10-Q: 3M Q3 2025: Sales Up, Litigation Costs Weigh on GAAP EPS

3M reports a 3.5% increase in net sales for Q3 2025, driven by strength in safety and electronics, but GAAP EPS declined significantly due to special items including litigation charges.

Summary

• Net sales for Q3 2025 increased by 3.5% year-over-year to $6,517 million, with organic sales up 2.6%.
• For the first nine months of 2025, net sales rose 1.3% to $18,815 million, and organic sales grew 1.0%.
• GAAP diluted earnings per share (EPS) for Q3 2025 was $1.55, a 38% decrease year-over-year, and $4.93 for the first nine months, down 17%.
• Adjusted diluted EPS, excluding special items, increased 10% to $2.19 in Q3 2025 and 11% to $6.23 for the first nine months.
• Operating income margin improved to 22.2% in Q3 2025 (up 1.3 ppts) and 20.4% for the first nine months (up 0.3 ppts).
• Cash flows from operating activities for the first nine months of 2025 increased by $0.7 billion to $723 million, primarily due to lower payments for PFAS-related environmental liabilities and the Combat Arms Earplugs (CAE) legal settlement.
• Total debt as of September 30, 2025, was $12,603 million, a decrease from $13,044 million at December 31, 2024.
• Net debt (non-GAAP) increased to $7,399 million as of September 30, 2025, from $5,300 million at December 31, 2024.
• Accrued liabilities for PFAS-related other environmental matters totaled $7.5 billion, for CAE litigation $2.5 billion, and for respirator mask/asbestos litigation $471 million as of September 30, 2025.
• The effective tax rate increased to 26.8% in Q3 2025 and 23.7% for the first nine months, primarily due to the tax impacts of 3M's retained ownership interest in Solventum, Pillar Two Model Rules, and loss on business divestiture.
• 3M sold a portion of its Solventum holdings for $0.6 billion in August 2025, retaining approximately 15% of Solventum's common stock with a fair value of $1.9 billion.

Sentiment

Score: 5

Explanation: While 3M shows modest organic sales growth and improved adjusted EPS, the company faces substantial and ongoing financial headwinds from significant litigation (PFAS, CAE, asbestos) and the complex, costly exit from PFAS manufacturing. The GAAP EPS decline reflects these challenges. The strong operating cash flow and share repurchase program are positive, but the magnitude of potential future liabilities and regulatory uncertainties create considerable uncertainty.

Positives

• Net sales increased by 3.5% in Q3 2025 and 1.3% in the first nine months of 2025, demonstrating overall revenue growth.
• Organic sales grew by 2.6% in Q3 2025 and 1.0% in the first nine months, indicating underlying business strength.
• Adjusted diluted EPS increased by 10% in Q3 2025 and 11% in the first nine months, reflecting improved profitability when excluding special items.
• Operating income margin improved by 1.3 percentage points in Q3 2025 and 0.3 percentage points in the first nine months, driven by growth, productivity, and lower restructuring costs.
• Cash flows from operating activities significantly increased by $0.7 billion in the first nine months of 2025, primarily due to reduced payments for major legal settlements.
• The Combat Arms Earplugs (CAE) Multidistrict Litigation (MDL) has been resolved, with over 99% claimant participation in the settlement, reducing a major source of uncertainty.
• Insurance recovery benefits of $182 million in Q3 2025 and $267 million in the first nine months of 2025 helped offset litigation costs.
• The Board of Directors authorized a new $7.5 billion share repurchase program in February 2025, demonstrating confidence in future cash generation and commitment to shareholder returns.
• 3M increased its quarterly dividend by 4% to $0.73 per share in February 2025, continuing its long history of dividend payments.

Negatives

• GAAP diluted EPS decreased significantly by 38% in Q3 2025 and 17% in the first nine months of 2025, primarily due to special items.
• Special items, including net costs for significant litigation, loss on business divestitures, and the change in value of Solventum ownership, continue to heavily impact reported financial results.
• A pre-tax charge of $161 million was recorded in Q3 2025 for the loss on business divestitures, specifically for the precision grinding and finishing business classified as held for sale.
• The change in value of Solventum ownership resulted in a $94 million expense in Q3 2025 and $242 million in the first nine months of 2025.
• The effective tax rate increased to 26.8% in Q3 2025 and 23.7% for the first nine months, driven by tax impacts related to Solventum ownership, Pillar Two Model Rules, and divestiture losses.
• The Consumer segment experienced soft consumer discretionary spending, partially offsetting growth from new product launches and increased investment.
• The Automotive Aftermarket business continued to show softness, impacting the Safety and Industrial segment.
• Net debt increased by $2,099 million from December 31, 2024, to September 30, 2025, indicating higher leverage.

Risks

• Worldwide economic, political, regulatory, international trade, geopolitical, and other external conditions, including inflation, recession, military conflicts, trade restrictions, and climate change, may adversely impact operations, demand, and profitability.
• Foreign currency exchange rate fluctuations can materially impact sales and earnings, especially with a significant portion of revenue derived from outside the U.S.
• Liabilities related to perand polyfluoroalkyl substances (PFAS) could have a material adverse effect, including costs of exiting manufacturing, discontinuing use, potential litigation, and increasingly stringent regulatory requirements globally.
• Unexpected events related to the Public Water Systems (PWS) Settlement for PFAS, including its potential impact on other PFAS-related matters, could materially affect results.
• Ongoing legal proceedings, including respirator mask/asbestos litigation, AFFF litigation, and other PFAS-related product and environmental lawsuits, pose significant financial and reputational risks, with outcomes often difficult to predict.
• The company's ability to meet growth objectives is dependent on the timing and market acceptance of new product offerings and the ability to continually renew its product pipeline.
• Vulnerability to fluctuations in the costs and availability of purchased components, raw materials, energy, and labor, as well as supply chain interruptions, could materially affect operations.
• Network disruptions, security and data breaches, cyberattacks, and other cybersecurity incidents involving information and operational technology systems could disrupt operations, compromise data, and lead to significant expenses and liabilities.
• Acquisitions, strategic alliances, divestitures (including the Solventum spin-off), and other strategic events may not achieve anticipated benefits or could result in unexpected liabilities and costs.
• Operational execution challenges, including organizational restructurings and failure to generate planned productivity improvements, could negatively impact sales, employee relationships, and customer experience.
• Defined benefit pension and postretirement plans are subject to financial market risks, such as changes in interest rates and investment losses, which could increase funding obligations.
• Changes in credit ratings or increases in benchmark interest rates could increase the cost of funding and adversely affect liquidity and access to capital markets.
• Changes in tax rates, laws, or regulations, including those related to Pillar Two Model Rules and BEPS, could adversely impact financial results.
• Risks related to the Combat Arms Earplugs (CAE) Settlement, such as future claims by non-participating plaintiffs or new litigation, could have a material adverse effect.
• The Solventum spin-off could result in unrealized benefits, higher costs, impacts on relationships with stakeholders, inability to find suitable alternative goods/services, and market volatility of retained Solventum shares.
• The development and use of artificial intelligence technology may present risks, including legal and regulatory challenges, data breaches, and intellectual property issues.

Future Outlook

3M expects 2025 capital spending to be approximately $0.9 billion, reflecting continued investment in growth, productivity, and sustainability. The company is progressing toward exiting all PFAS manufacturing and discontinuing the use of PFAS across its product portfolio by the end of 2025, though it continues to evaluate circumstances where third-party manufactured PFAS-containing products may be used beyond 2025 in certain applications. 3M intends to divest its remaining ownership interest in Solventum within five years of its 2024 spin-off. The company also anticipates ongoing implementation of new business systems and solutions, including an enterprise resource planning (ERP) system, which are expected to improve efficiency.

Management Comments

• "3M is progressing toward the exit of PFAS manufacturing by the end of 2025."
• "The Company continues to discuss its PFAS manufacturing exit, and related issues involving the disposition of manufacturing assets, with customers, government authorities, and other stakeholders, and the Company remains focused on completing the exit in a timely and orderly fashion."
• "3M is working to discontinue the use of PFAS across its product portfolio by the end of 2025 and has made progress in eliminating the use of PFAS across its product portfolio in a variety of applications."
• "The Company expects 2025 capital spending to be approximately $0.9 billion as 3M continues to invest in growth, productivity and sustainability."
• "3M believes it will have continuous access to the commercial paper market."
• "3M's strong balance sheet and liquidity provide the Company with significant flexibility to fund its numerous opportunities going forward."

Industry Context

The filing highlights accelerating global regulatory and legislative activities concerning PFAS, with increasingly stringent restrictions and lower limits for PFAS in emissions and environmental media, indicating a broad industry shift away from these substances. This trend impacts 3M's manufacturing operations and product portfolio, necessitating significant strategic adjustments. The Consumer segment's performance is affected by soft consumer discretionary spending, reflecting broader economic pressures on consumer goods. Performance across industrial sectors is mixed, with softness in the automotive aftermarket contrasting with momentum in aerospace and electronics, suggesting varied demand drivers within 3M's diversified portfolio.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for benchmarking 3M's performance against industry standards. The analysis focuses on 3M's internal performance metrics and general industry trends.

Corporate Governance

Legal Proceedings

• Respirator Mask/Asbestos Litigation: Approximately 3,600 individual claimants are involved in lawsuits. The company increased accruals by $28 million in the first nine months of 2025, with a total accrual of $471 million as of September 30, 2025. A bench trial in West Virginia is expected to resume in November 2025.
• Aearo Technologies (Respirator Mask/Asbestos): Accruals of $53 million as of September 30, 2025, for product liabilities and defense costs related to current and future Aearo-related asbestos, silica-related, and coal mine dust claims. Liability is limited by an agreement with Cabot.
• PFAS-Related Environmental Matters and Litigation: 3M is committed to exiting all PFAS manufacturing by the end of 2025 and discontinuing use across its product portfolio. Accrued liabilities for PFAS-related other environmental matters totaled $7.5 billion as of September 30, 2025, an increase of approximately $0.7 billion in the first nine months of 2025, with related payments of $1.8 billion.
• New Jersey Settlement: 3M agreed to a proposed Judicial Consent Order with the State of New Jersey to pay up to $450 million, recording a pre-tax charge of $281 million in Q2 2025. Payments are expected to begin in 2026 and run through 2050.
• Aqueous Film Forming Foam (AFFF) Litigation: Over 13,900 cases are pending in a consolidated multi-district litigation (MDL). The Public Water Systems (PWS) Settlement, approved in March 2024, requires 3M to pay $10.5 billion to $12.5 billion, with payments from 2024 through 2036. The first bellwether personal injury trial, scheduled for October 2025, was vacated.
• Combat Arms Earplugs (CAE) Litigation: The CAE Multidistrict Litigation (MDL) has been resolved, with over 99% claimant participation in the settlement. 3M will contribute up to $6.0 billion between 2023 and 2029. The accrued liability for CAE was $2.5 billion as of September 30, 2025, with payments of approximately $1.4 billion made in the first nine months of 2025.
• Other Regulatory Matters: 3M settled with OSHA and the DOL for an immaterial amount related to an employee fatality at its Prairie du Chien facility. The company is cooperating with a grand jury subpoena from the U.S. Attorney's Office for the Western District of Wisconsin related to the Prairie du Chien facility and other 3M facilities.

Related Party Transactions

• 3M has continuing involvement with Solventum following its April 2024 separation, including net sales under supply agreements and income from transition agreements.
• Amounts due from Solventum under these agreements were approximately $0.4 billion as of September 30, 2025.
• Amounts due to Solventum under these agreements were approximately $0.2 billion as of September 30, 2025.

Stakeholder Impact

• Shareholders: Impacted by significant GAAP EPS decline due to special items, but also by adjusted EPS growth, increased dividends, and a new share repurchase program. Ongoing litigation and PFAS exit create uncertainty.
• Employees: Affected by restructuring actions, with approximately 7,000 positions impacted by the 2023-2025 structural reorganization and 1,200 positions by the PFAS exit restructuring.
• Customers: Potential for supply disruptions or changes in product offerings due to the PFAS exit and evolving regulatory requirements.
• Communities/Environment: Significant environmental liabilities and ongoing remediation efforts related to PFAS contamination, particularly in areas like Alabama, Illinois, Minnesota, and various international locations.
• Suppliers: May experience changes in demand or requirements as 3M transitions away from PFAS-containing materials and products.

Next Steps

• Continue progressing toward exiting all PFAS manufacturing by the end of 2025.
• Work to discontinue the use of PFAS across its product portfolio by the end of 2025.
• Divest its remaining ownership interest in Solventum within five years of the 2024 spin-off.
• Implement new business systems and solutions, including an enterprise resource planning (ERP) system, on an ongoing basis.
• Invest approximately $0.9 billion in capital spending for 2025 to drive growth, productivity, and sustainability.
• Resume the initial bench trial in the State of West Virginia's respirator mask/asbestos action in November 2025.
• Continue to address various ongoing legal proceedings and regulatory compliance matters related to PFAS, AFFF, and other product liabilities.
• Conduct product-identification discovery for approximately 15 sites allegedly contaminated with PFAS from AFFF use, as directed by the AFFF MDL court.
• Engage in discussions with ADEM regarding 3M's application for a modified NPDES permit for the Decatur facility.
• Engage in discussions with IEPA regarding 3M's application for a modified NPDES permit for the Cordova facility.
• Continue to work with MPCA to address the Notice of Violation regarding wastewater and stormwater discharge from the Cottage Grove facility.
• Continue the mediation process with MPCA to address disagreements regarding the Minnesota 2018 Natural Resources Defense Settlement.
• Submit a work plan for investigation at the Wausau Greystone facility as ordered by the Wisconsin Department of Natural Resources (WDNR).
• Develop a site characterization plan to investigate suspected PFAS releases at the Cynthiana, Kentucky facility.
• Engage in discussions with the Indiana Department of Environmental Management (IDEM) regarding notices of liability for investigation and remediation at the Hartford City facility.

Key Dates

Recommendation

While 3M demonstrates modest organic sales growth and improved adjusted EPS, the company faces substantial and ongoing financial headwinds from significant litigation (PFAS, CAE, asbestos) and the complex, costly exit from PFAS manufacturing. The GAAP EPS decline reflects these challenges. The strong operating cash flow and share repurchase program are positive, but the magnitude of potential future liabilities and regulatory uncertainties warrant a cautious 'hold' stance for investors until there is greater clarity on the ultimate financial impact of these long-term issues.

Keywords

3M, MMM, SEC filing, 10-Q, quarterly report, financial results, PFAS, PFOA, PFOS, AFFF, Combat Arms Earplugs, CAE, Solventum, spin-off, divestitures, litigation, environmental liabilities, product liability, earnings, revenue, operating income, EPS, cash flow, debt, share repurchase, dividends, risk factors, manufacturing, industrial, electronics, consumer